Pharmaceutical Manufacturing - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2027 - 2032)
Pharmaceutical Manufacturing Market Analysis According to Mordor Intelligence, the pharmaceutical manufacturing market size is projected to expand from USD 549.2 billion in 2026 and USD 603.7 ... もっと見る
英語原文をAIを使って翻訳しています。
SummaryPharmaceutical Manufacturing Market AnalysisAccording to Mordor Intelligence, the pharmaceutical manufacturing market size is projected to expand from USD 549.2 billion in 2026 and USD 603.7 billion in 2027 to USD 945.2 billion by 2032, registering a CAGR of 9.38% between 2027 and 2032. This report is segmented by Molecule Type (Conventional Drugs and more), Manufacturing Mode (CMO / CDMO and more), Formulation (Tablets and more), Manufacturing Technology (Batch and more), Application (Oncology and more), Prescription Type (Prescription and more), and Geography (North America and more). The market forecasts are provided in terms of value (USD), based on availability. Global Pharmaceutical Manufacturing Market Trends and InsightsRising R&D investments by Big PharmaRising research budgets can increase manufacturing demand when funded medicines advance toward production. GSK plc's total research and development expense increased 18% at actual exchange rates in 2025 versus 2024, or 19% at constant exchange rates. Novo Nordisk's 2025 R&D reorganization brought manufacturability and supply considerations earlier into drug development. For drug owners, earlier manufacturing input can make process requirements part of development choices instead of a later capacity decision. Bringing those decisions forward can advance demand for process-development work and capacity planning before a medicine reaches commercial production. Integration of AI-enabled Automation in Legacy LinesFor an existing production line, the commercial test for an AI-enabled retrofit is whether it improves usable medicine output from equipment already in place. An AI-enabled retrofit adds analytics to equipment already installed, so its case rests on the extra specification-conforming output it releases from that equipment. A retrofit that increases specification-conforming output can support additional medicine supply while reducing the need for a comparable addition of physical capacity. Its contribution to manufacturing growth therefore depends on extra conforming units reaching sale. A producer facing added demand therefore measures the retrofit by the conforming units it adds to sellable supply from the existing building. Global drug-pricing pressure & cost-containmentDrug-pricing pressure weakens the revenue available to support manufacturing even when medicines retain a treatment role. Merck & Co reported that global cost-containment efforts pressured pricing and market access in 2025, with government-mandated price reductions in several international markets. Worldwide combined sales of its Januvia and Janumet fell 31% to USD 429 million in Q2 2026 versus Q2 2025. Merck & Co cited lower US demand and net pricing due to competition, alongside lower Chinese demand and generic competition in other international markets. These mechanisms affect both the value captured per sale and the volume requiring production, making additional capacity an incomplete response. For exposed manufacturers, lower net prices narrow cost recovery while weaker demand reduces the output over which production costs can be spread. Other drivers and restraints analyzed in the detailed report include:
For complete list of drivers and restraints, kindly check the Table Of Contents. Segment AnalysisConventional drugs accounted for a 51.91% share of the pharmaceutical manufacturing market size in 2026. In its 2025 sustainability report, Hikma reported annual US capacity for more than 12 billion finished doses of essential medicines and a portfolio exceeding 800 products, including over 180 sterile injectable medicines. Hikma describes its US portfolio as generic medicines. This combination of dose scale and product breadth gives established manufacturers a production base serving multiple medicine requirements. Hikma's dose scale and portfolio breadth show conventional output depending on keeping many established medicines in continuous supply, which high-volume US plants make possible. Biologics and biosimilars are the fastest-growing segment, with a projected 10.08% CAGR during 2027-2032. Complex modalities, including bi- and multispecific antibodies and antibody-drug conjugates, contributed more than half of WuXi Biologics' group revenue in H1 2026. Lonza's Integrated Biologics platform recorded 10% constant-currency sales growth in H1 2026 versus H1 2025. WuXi's revenue mix gives complex-modality expertise a direct role in serving its programs, while Lonza's sales result shows expansion in biologics development and manufacturing activity. Complex antibodies and antibody-drug conjugates need molecule-specific process capabilities, so WuXi Biologics' modality mix and Lonza's growth point to specialized suppliers rather than interchangeable capacity. CMO / CDMO production represented a 59.9% pharmaceutical manufacturing market share in 2026 and is the fastest-growing segment, with a 10.12% CAGR forecast during 2027-2032. WuXi Biologics' manufacturing revenue grew 26.4% in 2025 versus 2024, supported by project progression and the ramp-up of existing projects. Samsung Biologics also secured a manufacturing agreement with a European pharmaceutical company in Q4 2025. That agreement illustrates how drug owners can secure production services through a commercial relationship with a specialist provider. Providers capture the manufacturing opportunity when their capabilities remain relevant as projects move from development toward recurring production. In-house manufacturing preserves a different form of control over linked production steps. In February 2026, Novo Nordisk reported US in-house Wegovy pill production, with active ingredients made at its Clayton, North Carolina, site and tablets made and packed at its Durham, North Carolina, site. This connects the same drug owner's upstream and finished-dose operations across separate sites. For a product owner, that arrangement can make the coordination of ingredient output, tablet manufacture and packing an internal operational decision. Manufacturing mode determines who coordinates the production chain, with in-house owners setting ingredient and tablet sequencing internally and outsourcing owners placing that coordination with providers. Complete Report Scope:
Geography AnalysisNorth America held a 36.41% pharmaceutical manufacturing market share in 2026. In September 2025, FUJIFILM Biotechnologies, a contract manufacturing subsidiary of FUJIFILM Corporation, opened the first phase of its planned USD 3.2 billion commercial-scale cell-culture manufacturing site in Holly Springs, North Carolina. The opened phase included 8 mammalian cell-culture bioreactors, each 20,000 liters, with manufacturing scope spanning drug substance and drug product. The site's combination of large-scale cell culture and drug-product capability illustrates a supply base supporting North America's lead, with drug owners able to source both production stages within the region. Asia-Pacific is the fastest-growing geography, with a 10.6% CAGR forecast during 2027-2032. In October 2025, Lilly announced an INR 90 billion (USD 1 billion) investment to expand its contract manufacturing operations in Hyderabad, India. Duopharma Biotech increased sterile cephalosporin capacity at its Klang, Malaysia, facility from 600,000 to 800,000 vials per month starting in Q3 2025. The Indian announcement concerns contract-manufacturing expansion, while the Malaysian result shows a completed increase in capacity for a specific medicine category. Regional manufacturers face different expansion choices, with production partnerships and sterile-vial capacity offering separate paths into local manufacturing activity. In Europe, Gedeon Richter Polska began expanding its medicine plant in Grodzisk Mazowiecki, Poland, in February 2025, estimating about 30% additional company production capacity. In the Middle East and Africa region, Jamjoom Pharma's Egypt facility produced 29 million units in 2025, up from 24.9 million in 2024. In South America, Brazil recorded 6.3 billion medicine packages sold across 14,371 presentations in 2025. Colombia's Gonher announced the opening of its Plant 3 and Plant 4 in Bogotá in June 2025. Gedeon Richter ties its Grodzisk Mazowiecki expansion to medicine security in Poland and Europe, while Brazil's broad presentation range makes supplying a varied medicine assortment a separate test for manufacturers. List of Companies Covered in this Report:
Additional Benefits:
Table of Contents1 INTRODUCTION1.1 Study Assumptions and Market Definition 1.2 Scope of the Study 2 RESEARCH METHODOLOGY 3 EXECUTIVE SUMMARY 4 MARKET LANDSCAPE 4.1 Market Overview 4.2 Market Drivers 4.2.1 Rising R&D investments by Big Pharma 4.2.2 Integration of AI-enabled Automation in Legacy Lines 4.2.3 Biosimilar surge after key patent cliffs 4.2.4 Reshoring & localization of API capacity 4.2.5 Decentralized micro-batch lines for personalized meds 4.2.6 Heat- & solvent-free 3-D printing of tablets 4.3 Market Restraints 4.3.1 Global drug-pricing pressure & cost-containment 4.3.2 Critical-input supply-chain fragility 4.3.3 Shortage of GMP-grade recycled solvents 4.3.4 Cyber-security liability in connected plants 4.4 Industry Value Chain Analysis 4.5 Regulatory Landscape 4.6 Technological Outlook 4.7 Porter's Five Forces Analysis 4.7.1 Threat of New Entrants 4.7.2 Bargaining Power of Suppliers 4.7.3 Bargaining Power of Buyers 4.7.4 Threat of Substitutes 4.7.5 Competitive Rivalry 5 MARKET SIZE AND GROWTH FORECASTS (VALUE) 5.1 By Molecule Type 5.1.1 Biologics & Biosimilars 5.1.2 Conventional Drugs 5.2 By Manufacturing Mode 5.2.1 In-house 5.2.2 CMO / CDMO 5.3 By Formulation 5.3.1 Tablets 5.3.2 Capsules 5.3.3 Injectables 5.3.4 Topical & Transdermal 5.3.5 Nasal & Pulmonary Sprays 5.3.6 Others 5.4 By Manufacturing Technology 5.4.1 Batch 5.4.2 Continuous 5.4.3 Single-Use 5.5 By Application 5.5.1 Oncology 5.5.2 Diabetes 5.5.3 Cardiovascular 5.5.4 Neurology 5.5.5 Respiratory 5.5.6 Others 5.6 By Prescription Type 5.6.1 Prescription 5.6.2 Over-the-Counter (OTC) 5.7 By Geography 5.7.1 North America 5.7.1.1 United States 5.7.1.2 Canada 5.7.1.3 Mexico 5.7.2 Europe 5.7.2.1 Germany 5.7.2.2 United Kingdom 5.7.2.3 France 5.7.2.4 Italy 5.7.2.5 Spain 5.7.2.6 Rest of Europe 5.7.3 Asia-Pacific 5.7.3.1 China 5.7.3.2 India 5.7.3.3 Japan 5.7.3.4 Australia 5.7.3.5 South Korea 5.7.3.6 Rest of Asia-Pacific 5.7.4 Middle East and Africa 5.7.4.1 GCC 5.7.4.2 South Africa 5.7.4.3 Rest of Middle East and Africa 5.7.5 South America 5.7.5.1 Brazil 5.7.5.2 Argentina 5.7.5.3 Rest of South America 6 COMPETITIVE LANDSCAPE 6.1 Market Concentration 6.2 Strategic Moves 6.3 Market Share Analysis 6.4 Company Profiles (includes Global level Overview, Market level overview, Core Segments, Financials as available, Strategic Information, Market Rank/Share for key companies, Products and Services, and Recent Developments) 6.4.1 AbbVie Inc 6.4.2 Amgen 6.4.3 AstraZeneca plc 6.4.4 BMS 6.4.5 Boehringer Ingelheim 6.4.6 Catalent 6.4.7 Cipla 6.4.8 GSK plc 6.4.9 Lilly 6.4.10 Lonza 6.4.11 Merck & Co 6.4.12 Novartis 6.4.13 Novo Nordisk 6.4.14 Pfizer Inc 6.4.15 F. Hoffmann-La Roche AG 6.4.16 Sanofi SA 6.4.17 Sun Pharma 6.4.18 Takeda 6.4.19 Teva 7 MARKET OPPORTUNITIES AND FUTURE OUTLOOK 7.1 White-Space and Unmet-Need Assessment
ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。本レポートと同分野(医療/ヘルスケア)の最新刊レポート
Mordor Intelligence社の ヘルスケア分野 での最新刊レポート
本レポートと同じKEY WORD(pharmaceutical)の最新刊レポート
よくあるご質問Mordor Intelligence社はどのような調査会社ですか?Mordor Intelligenceは世界の多様な市場に関する重要動向、技術、競争、機会について調査しています。 もっと見る 調査レポートの納品までの日数はどの程度ですか?在庫のあるものは速納となりますが、平均的には 3-4日と見て下さい。
注文の手続きはどのようになっていますか?1)お客様からの御問い合わせをいただきます。
お支払方法の方法はどのようになっていますか?納品と同時にデータリソース社よりお客様へ請求書(必要に応じて納品書も)を発送いたします。
データリソース社はどのような会社ですか?当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
|
|